NZ761547B2 - Bispecific antibody - Google Patents
Bispecific antibody Download PDFInfo
- Publication number
- NZ761547B2 NZ761547B2 NZ761547A NZ76154719A NZ761547B2 NZ 761547 B2 NZ761547 B2 NZ 761547B2 NZ 761547 A NZ761547 A NZ 761547A NZ 76154719 A NZ76154719 A NZ 76154719A NZ 761547 B2 NZ761547 B2 NZ 761547B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims abstract 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 6
- 208000024891 symptom Diseases 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 96
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 33
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 33
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 7
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102400000739 Corticotropin Human genes 0.000 claims 3
- 101800000414 Corticotropin Proteins 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
- 229960000258 corticotropin Drugs 0.000 claims 3
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Chemical group 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- -1 alemtuzumab Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010048628 rheumatoid vasculitis Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000008899 Habitual abortion Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000021330 IgG4-related disease Diseases 0.000 claims 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036697 Primary hypothyroidism Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 206010003883 azoospermia Diseases 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 231100001016 megaloblastic anemia Toxicity 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950000844 mizoribine Drugs 0.000 claims 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002568 urticarial effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 206010051792 Infusion related reaction Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune diseases, or the treatment of autoimmune diseases. As a result of diligent investigation, the inventors of the present invention have focused on PD-1/CD3 bispecific antibodies as substances that can solve the abovementioned problem and have confirmed that said bispecific antibodies make it possible to achieve pharmaceuticals that reduce the occurrence of the adverse effects known as infusion-related reaction and cytokine release syndrome. In addition, the inventors have confirmed that said bispecific antibodies allow for interaction between PD-1 and its ligand PD-L1 and have discovered that said feature contributes to enhanced and sustained activity.
Claims (36)
1. A PD-1/CD3 bispecific antibody or antibody fragment thereof, comprising the first arm specifically binding to PD-1 and the second arm specifically binding to CD3, wherein the first arm specifically binding to PD-1 comprises any one of VH selected from: (A) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 18; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 19; and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 20; (B) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 6; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 7; and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 8; (C) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 9; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 10; and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 11; (D) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 12; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 13, and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 14; and (E) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 15; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 16; and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 17; and (F) a VL having (a) a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 26; (b) a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 27; and (c) a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 28; and wherein the second arm specifically binding to CD3 comprises: (A) a VH having (a) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37; (b) a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38; and (c) a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39, and (B) a VL having (a) a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 26; (b) a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 27; and (c) a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 28.
2. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein (i) the VH of the first arm specifically binding to PD-1 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 18, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 19, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 20; and (ii) the VH of the second arm specifically binding to CD3 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
3. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein (i) the VH of the first arm specifically binding to PD-1 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 6, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 7, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 8; and (ii) the VH of the second arm specifically binding to CD3 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
4. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein (i) the VH of the first arm specifically binding to PD-1 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 9, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 10, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 11; and (ii) the VH of the second arm specifically binding to CD3 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
5. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein (i) the VH of the first arm specifically binding to PD-1 has (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 12, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 13, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 14, and (ii) the VH of the second arm specifically binding to CD3 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
6. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein (i) the VH of the first arm specifically binding to PD-1 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 15, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 16, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 17; and (ii) the VH of the second arm specifically binding to CD3 has: (a) the VH-CDR1 comprising the amino acid sequence set forth in SEQ ID No. 37, (b) the VH-CDR2 comprising the amino acid sequence set forth in SEQ ID No. 38, and (c) the VH-CDR3 comprising the amino acid sequence set forth in SEQ ID No. 39.
7. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 6, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in any one selected from SEQ ID No. 5, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4, or an amino acid sequence having at least 80% identity to VH amino acid sequence thereof.
8. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 7, wherein the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36, or an amino acid sequence having an identity of at least 80% to VH amino acid sequence thereof.
9. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in any one selected from SEQ ID No. 5, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
10. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1 or 2, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in SEQ ID No. 5; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
11. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1 or 3, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in SEQ ID No. 1; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
12. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1 or 4, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in SEQ ID No. 2; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
13. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1 or 5, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in SEQ ID No. 3; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
14. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1 or 6, wherein the VH of the first arm specifically binding to PD-1 comprises the amino acid sequence set forth in SEQ ID No. 4; and the VH of the second arm specifically binding to CD3 comprises the amino acid sequence set forth in SEQ ID No. 36.
15. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 14, wherein the first arm specifically binding to PD-1 and/or the second arm specifically binding to CD3 have the VL comprising the amino acid sequence set forth in SEQ ID No. 25.
16. A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the first arm specifically binding to PD-1 and the second arm specifically binding to CD3, wherein (A) the first arm specifically binding to PD-1 has the VH comprising the amino acid sequence set forth in any one selected from SEQ ID No. 5, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4, and the VL comprising the amino acid sequence set forth in SEQ ID No. 25; and (B) the second arm specifically binding to CD3 has the VH comprising the amino acid sequence set forth in SEQ ID No. 36; and the VL comprising the amino acid sequence set forth in SEQ ID No. 25.
17. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 16, wherein the PD-1/CD3 bispecific antibody is an IgG antibody.
18. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 17, which is an IgG antibody or an IgG antibody.
19. The PD-1/CD3 bispecific antibody or an antibody fragment thereof according to claim 17, which is an IgG antibody.
20. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 19, wherein the binding to an Fc receptor is eliminated or reduced.
21. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 20, wherein in two heavy chain constant regions of the PD-1/CD3 bispecific IgG antibody, leucine at position 235 according to the EU numbering system is substituted with glycine, and/or glycine at position 236 according to the EU numbering system is substituted with arginine.
22. The PD-1/CD3 bispecific antibody or an antibody fragment thereof according to any one of claims 19 to 21, wherein in a constant region of a heavy chain having a VH of the first arm specifically binding to PD-1, leucine at position 351 according to the EU numbering system is substituted with lysine and threonine at position 366 according to the EU numbering system is substituted with lysine; and in a constant region of a heavy chain having a VH of the second arm specifically binding to CD3, leucine at position 351 according to the EU numbering system is substituted with aspartic acid and leucine at position 368 according to the EU numbering system is substituted with glutamic acid.
23. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 19 to 21, wherein in a constant region of a heavy chain having a VH of the first arm specifically binding to PD-1, leucine at position 351 according to the EU numbering system is substituted with aspartic acid, and leucine at position 368 is substituted with glutamic acid, and in a constant region of a heavy chain having a VH of the second arm specifically binding to CD3, leucine at position 351 according to the EU numbering system is substituted with lysine, and threonine at position 366 according to the EU numbering system is substituted with lysine.
24. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 19 to 23, wherein in two heavy chain constant regions of the PD-1/CD3 bispecific antibody, lysine at position 447 according to the EU numbering system is deleted.
25. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 18, wherein the PD-1/CD3 bispecific antibody is an IgG antibody, and in two heavy chain constant regions, serine at position 228 according to the EU numbering system is substituted with proline, respectively.
26. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 20, wherein the heavy chain having the VH of the first arm specifically binding to PD-1 has a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 23.
27. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 20 or 26, wherein the heavy chain having the VH of the second arm specifically binding to CD3 has a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 24.
28. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 27, wherein the light chain having the VL of the first arm specifically binding to PD-1 and/or the light chain having VL of the second arm specifically binding to CD3 have a light chain constant region comprising the amino acid sequence set forth in SEQ ID No. 29.
29. A PD-1/CD3 bispecific antibody or antibody fragment thereof, having the first arm specifically binding to PD-1 and the second arm specifically binding to CD3, wherein: (A) a heavy chain having the VH of the first arm specifically binding to PD-1 has the VH comprising the amino acid sequence set forth in any one selected from SEQ ID No. 5, SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4, and the heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 23; (B) a light chain having the VL of the first arm specifically binding to PD-1 has the VL comprising the amino acid sequence set forth in SEQ ID No. 25, and the light chain constant region comprising the amino acid sequence set forth in SEQ ID No. 29; (C) a heavy chain having the VH of the second arm specifically binding to CD3, has the VH comprising the amino acid sequence set forth in SEQ ID No. 36, and the heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 24; and (D) a light chain having the VL of the second arm specifically binding to CD3 has the VL comprising the amino acid sequence set forth in SEQ ID No. 25, and the light chain constant region comprising the amino acid sequence set forth in SEQ ID No. 29.
30. A PD-1/CD3 bispecific antibody having the first arm specifically binding to PD-1 and the second arm specifically binding to CD3, wherein: (A) a heavy chain having the VH of the first arm specifically binding to PD-1 has the VH comprising the amino acid sequence set forth in SEQ ID No. 5, and the heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 23; (B) a light chain having the VL of the first arm specifically binding to PD-1 has the VL comprising the amino acid sequence set forth in SEQ ID No. 25, and the light chain constant region comprising the amino acid sequence set forth in SEQ ID No. 29; (C) a heavy chain having the VH of the second arm specifically binding to CD3, has the VH comprising the amino acid sequence set forth in SEQ ID No. 36, and the heavy chain constant region comprising the amino acid sequence set forth in SEQ ID No. 24; and (D) a light chain having the VL of the second arm specifically binding to CD3 has the VL comprising the amino acid sequence set forth in SEQ ID No. 25, and the light chain constant region comprising the amino acid sequence set forth in SEQ ID No. 29.
31. A pharmaceutical composition comprising the PD-1/CD3 bispecific antibody or antibody fragment thereof selected from any one of claims 1 to 30, and a pharmaceutically acceptable carrier.
32. Use of the PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 30 in the manufacture of a medicament for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases.
33. The use according to claim 32, wherein the autoimmune diseases include Behcet's disease, systemic lupus erythematosus, chronic discoid lupus erythematosus, multiple sclerosis, scleroderma, polymyositis, dermatomyositis, periarteritis nodosa, aortitis syndrome, malignant rheumatoid arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, mixed connective tissue disease, Sjogren's syndrome, adult Still's disease, vasculitis, allergic granulomatous vasculitis, hypersensitivity vasculitis, rheumatoid vasculitis, large vessel vasculitis, ANCA associated vasculitis, Cogan's syndrome, RS3PE, temporal arteritis, polymyalgia rheumatica, fibromyalgia, antiphospholipid antibody syndrome, eosinophilic fasciitis, IgG4-related disease, Guillain-Barre syndrome, myasthenia gravis, chronic atrophic gastritis, autoimmune hepatitis, non-alcoholic steatohepatitis, primary biliary cirrhosis, Goodpasture's syndrome, rapidly progressive glomerulonephritis, megaloblastic anemia, autoimmune hemolytic anemia, pernicious anemia, autoimmune neutropenia, idiopathic thrombocytopenic purpura, Basedow disease, Hashimoto disease, autoimmune adrenal insufficiency, primary hypothyroidism, Addison's disease, idiopathic Addison's disease, type I diabetes mellitus, slowly progressive type I diabetes mellitus, focal scleroderma, psoriasis, psoriatic arthritis, bullous pemphigoid, pemphigus, pemphigoid, gestational herpes, linear IgA bullous dermatosis, acquired epidermolysis bullosa, alopecia areata, vitiligo, vitiligo vulgaris, neuromyelitis optica, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, sarcoidosis, giant cell arteritis, amyotrophic lateral sclerosis, Harada disease, autoimmune optic neuropathy, idiopathic azoospermia, habitual abortion, inflammatory bowel disease, celiac disease, ankylosing spondylitis, severe asthma, chronic urticarial, transplantation immunity, familial mediterranean fever, eosinophilic chronic rhinosinusitis, dilated cardiomyopathy, systemic mastocytosis, or inclusion body myositis.
34. The use according to claim 32 or 33, wherein the medicament is to be administered together with one or more agent(s) selected from an insulin formulation, sulfonylurea agent, quick-acting insulin secretion promoter, biguanide preparation, insulin resistance improving agent, a-glucosidase inhibitor, diabetic neuropathy therapeutic agent, GLP-1 analog preparation, and DPP-4 inhibitor, steroid agent, interferon ß-1a, interferon ß-1b, glatiramer acetate, mitoxantrone, azathioprine, cyclophosphamide, cyclosporin, methotrexate, cladribine, adrenocorticotropic hormone (ACTH), corticotropin, mizoribine, tacrolimus, fingolimod, alemtuzumab, immunosuppressive agent, belimumab, anti-rheumatic drug, anti-cytokine drug, and abatacept.
35. Use of the PD-1/CD3 bispecific antibody or antibody fragment thereof according to any one of claims 1 to 30 in the manufacture of a medicament for preventing, suppressing symptom progression or recurrence of, and/or treating graft-versus-host disease (GVHD).
36. The PD-1/CD3 bispecific antibody or antibody fragment thereof according to claim 1, substantially as herein described with reference to any one of the Examples and/or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018021498 | 2018-02-09 | ||
JP2018153149 | 2018-08-16 | ||
PCT/JP2019/004551 WO2019156199A1 (en) | 2018-02-09 | 2019-02-08 | Bispecific antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ761547A NZ761547A (en) | 2023-11-24 |
NZ761547B2 true NZ761547B2 (en) | 2024-02-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6844719B2 (en) | Bispecific antibody | |
JP2018509413A5 (en) | ||
JP2013517799A (en) | CD127 binding protein | |
JP7476997B2 (en) | Bispecific antibodies | |
JP2024009224A (en) | bispecific antibody | |
NZ761547B2 (en) | Bispecific antibody | |
JP6856183B1 (en) | Bispecific antibody | |
JP2022060182A5 (en) | ||
JP2021075580A5 (en) | ||
RU2021128262A (en) | BISPECIFIC ANTIBODY | |
RU2814713C2 (en) | Bispecific antibody | |
US20220227887A1 (en) | Immunosuppressant | |
RU2796019C9 (en) | Bispecific antibody | |
JP2022060182A (en) | Pharmaceutical composition comprising bispecific antibody as active ingredient |